>Go!
NEWS SEARCH

05.02.2017 | Investors

Allergan Solidifies Strong Footprint at ARVO 2017 with Several Data Presentations

Novel Research in Retina, Glaucoma and Dry Eye will be Presented

DUBLIN, May 2, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that  23 Allergan-supported abstracts were selected for poster presentations at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO)  in Baltimore, Maryland from May 7-11, 2017.

Allergan plc logo

Building on a nearly 60-year heritage in ophthalmology with expertise in discovering and developing new therapeutic agents to preserve and protect vision, these presentations further establish Allergan as a leading global pharmaceutical company. The breadth of abstracts to be presented showcases Allergan's dedication to research and innovation in the area of ophthalmology.

The scheduled times (noted in local Eastern Time) of the 23 Allergan presentations, presentation titles, locations and authors are as follows:

Retina Poster Presentations

- Interspecies Comparison of Small Molecule Distribution into the Aqueous Chamber Following Intravitreal Administration

  • Date and Time: Sunday, May 7, 1:30-3:15 PM
  • Location: Posterboard A0305, Session 132, AMD and anti-VEGF therapy 1
  • Authors: J.R. Seal, W. Orilla, E. Chow, J.A. Burke and J. Shen

 

- Brimonidine Drug Delivery System (Brimo DDS Generation 1) Slows the Growth of Retinal Pigment Epithelial Hypofluorescence Following Regional Blue Light Irradiation on a Nonhuman Primate (NHP) Model of Geographic Atrophy (GA)

  • Date and Time: Monday, May 8, 11:00AM-12:45PM
  • Location: Posterboard B0464, Session 249, AMD: New Drugs, Delivery Systems
  • Authors: C. Ghosn, A. Almazan, S.Decker, J.Burke

 

- Brimonidine Drug Delivery System (DDS) Generation 1 in Patients with Geographic Atrophy: Post-hoc Analysis of a Phase 2 Study

  • Date and Time: Monday, May 8, 11:00AM-12:45PM
  • Location: Posterboard B0428, Session 248, AMD Therapies (excluding anti-VEGF)
  • Authors: B.D. Kuppermann, S.S. Patel, D.S. Boyer, A.J. Augustin, W.R. Freeman, T. Kim, K.J. Kerr, F.J. López and S. Schneider

 

- Persistent Diabetic Macular Edema After 6 Months of anti-VEGF Therapy is Associated with Diminished Long-Term Improvement in Vision: A Post-Hoc Analysis of Protocol I

  • Date and Time: Monday, May 8, 11:00AM-12:45PM
  • Location: Posterboard B0410, Session 247, Diabetic Macular Edema and anti-VEGF Therapy
  • Authors: S. Whitcup, J. Campbell, A.L oewenstein, P. Dugel, N. Holekamp, S. Kiss, A. Augustin, V. Shih, J. Lai, C. Wykoff and S.R. Sadda

 

- Abicipar Pegol in Neovascular Age-Related Macular Degeneration (nAMD): Comparability Between Japanese and Non-Japanese Patients, and Treatment Effects on Polypoidal Choroidal Vasculopathy (PCV) and non-PCV Patients

  • Date and Time: Monday, May 8, 11:00AM-12:45PM
  • Location: Posterboard B0463, Session 249, AMD: New Drugs, Delivery Systems
  • Authors: D.Y. Kunimoto, M. Ohji, R.K. Maturi, T. Sekiryu, Y. Wang, G.Pan, X.Y. Li and S. Schneider

 

- A Systematic Approach to Statistical Evaluation of Geographic Atrophy Clinical Studies

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard B0316, Session 284, AMD Clinical Research I
  • Authors: T. Kim, A. Mitchell, J. Liu, K. Kerr, F. Lopez and S. Schneider

 

- Comparison of Three Baseline Measures to Predict Geographic Atrophy Progression Rate in Clinical Studies

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard A0305, Session 132, AMD and anti-VEGF therapy 1
  • Authors: Q. Ho, M. Mackowski, K.J. Kerr, F.J. López and S. Schneider

 

- Optimized Dual Protein/miRNA Method to Quantitate Clinical Biomarkers of Ocular Disease

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard B0253, Session 283, AMD Translational Studies and Choroidal Neovascularization
  • Authors: M.A. Burton, J.J. Cunningham, G. Rodrigues and T.C. Hohman

 

- Qualification of a Multiplex Panel to Analyze Complement Proteins in Human Ocular Tissues

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard A0255, Session 283, AMD Translational Studies and Choroidal Neovascularization
  • Authors: M.A. Burton, J. Yang, P. Baciu and J.J. Cunningham

Glaucoma Poster Presentations

- In Vivo Angiographic Study of Normal Rabbit Aqueous Outflow

  • Date and Time: Sunday, May 7, 3:15PM-5:00PM
  • Location: Posterboard B0366, Session 159, Intraocular Pressure; Aqueous Humor Dynamics
  • Authors: S.S. Lee, A. Almazan, J.A. Burke and M.E. Robinson

 

- Evaluation of the Xen45 Gel Stent in Patients with Primary Angle Closure Glaucoma

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard A0174, Session 275, Clinical Trials and Drug Studies 1
  • Authors: F. Millan, M.E. Reveron, L. Gonzalez, M. Siso, C. Suescum, G.D. Novak, S.S. Lee and V. Vera

 

- Lower Levels of Adherence to Topical Glaucoma Mediations are Associated with Increased Risk of Visual Field Progression

  • Date and Time: Tuesday, May 9, 3:45PM-5:30PM
  • Location: Posterboard B0506, Session 384, Glaucoma
  • Authors: D. Fong, M. Batech, C. Mattox, T. Luong, J. Jimenez, J. Campbell and H. Chandwani

 

- Performance of a New Ab Interno Gelatin Stent in Refractory Glaucoma and 18-month Safety Results

  • Date and Time: Wednesday, May 10, 3:45PM-5:30PM
  • Location: Posterboard B0354, Session 484, Surgery and Would Healing
  • Authors: D.S. Grover, W.J. Flynn, K.P. Bashford, A. Sheybani, Y.J. Duh and B. Niksch

 

Dry Eye Poster Presentations

- Osmolarity-Dependently Protective Effects of Trehalose on Inflammatory Markers in Primary Human Corneal Epithelial Cells Exposed to Hyperosmotic Stress

  • Date and Time: Sunday, May 7, 1:30PM-3:15PM
  • Location: Posterboard A0417, Session 133, Dry Eye, Non-Clinical
  • Authors: Z. Liu, X. Chen, D. Chen, S.C. Pflugfelder and D.Q. Li

 

- Polymer Size and Other Physical Properties Vary Widely Among Hyaluronic Acid-Based Lubricant Eye Drops

  • Date and Time: Sunday, May 7, 1:30PM-3:15PM
  • Location: Posterboard A0379, Session 133, Dry Eye, Non-Clinical
  • Authors: P.A. Simmons, P. Aragona, H. Wang and T. Wang

 

- Intranasal Neurostimulator Induces Morphological Changes in Meibomian Glands in Patients with Dry Eye Disease

  • Date and Time: Monday, May 8, 3:45PM-5:30PM
  • Location: Posterboard B0002, Session 280, Lacrimal and Meibomian Glands
  • Authors: J.N. Pondelis, G. Dieckmann, P. Kataguiri, A. Abbouda, S. Zeina, M. Franke, M. Senchyna and P. Hamrah

 

- In Vivo Confocal Microscopy Demonstrates Intranasal Neurostimulation-Induced Globlet Cell Alterations in Patients with Dry Eye Disease

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0284, Session 315, Dry Eye, Clinical
  • Authors: G. Dieckmann, P. Kataguiri, N. Pondelis, A. Jamali, A. Abbouda, Z. Salem, M. Franke, M. Senchyna and P. Hamrah

 

- Quantitation of Tear Production by Tear Meniscus Height Following Acute Use of the Intranasal Tear Neurostimulator

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0282, Session 315, Dry Eye, Clinical
  • Authors: B. Orrick, M. Watson, E. Anjieli, M. Franke, M. Holdbrook, G. Ousler and M. Senchyna

 

- Evaluation of 0.05% Cyclosporine Ophthalmic Emulsion on Ocular Surface Staining and Visual Function in Subjects Who Engage in Electronic Visual Tasking

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0251, Session 315, Dry Eye, Clinical
  • Authors: K. Stonecipher, G. Torkildsen, E. McLaurin, L. Villanueva, G. Ousler and D.A. Hollander

 

- Tear Total LipidConcentration in Patients with Dry Eye Following Intranasal Neurstimulation

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0283, Session 315, Dry Eye, Clinical
  • Authors: K. Basso, M. Kamat, M. Franke, M. Holdbrook and M. Senchyna

 

- Clinical Evaluation of a Novel Lipid-Containing Lubricant Eye Drop with Omega-3 Oil and Trehalos

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0261, Session 315, Dry Eye, Clinical
  • Authors: M. Hom, G. Berdy, A. Verachtert, L. Downie, H. Liu, C. Carlisle, P. Simmons and J. Vehige

 

- Effect of Intranasal Neurostimulation on Tear Protein Content in Patients with Dry Eye

  • Date and Time: Tuesday, May 9, 8:30AM-10:15AM
  • Location: Posterboard A0263, Session 315, Dry Eye, Clinical
  • Authors: A.M. Woodward, M. Senchyna, M. Franke, M. Holdbrook and P. Argüeso

 

- Effect of Intranasal Tear Neurostimulator on Meibomian Glands

  • Date and Time: Wednesday, May 10, 11:00AM-12:45PM
  • Location: Posterboard A0226, Session 441, Conjunctival Cell Biol and Meibomian Glands
  • Authors: M. Watson, E. Angjieli, B. Orrick, S. Baba, M. Franke, M. Holdbrook, G. Ousler, D.A. Hollander, M. Senchyna

 

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: 

Investors:
Karina Calzadilla        
(862) 261-7328

Media:
Mark Marmur
(973) 906-1526

Suzanne Jacobson
(201) 273-4724

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-solidifies-strong-footprint-at-arvo-2017-with-several-data-presentations-300449463.html

SOURCE Allergan plc

Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488